supplementary_material.docx (21.43 kB)
Supplementary Material – Phase II, Clinical Trial of Cabozantinib for the Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplant
dataset
posted on 2022-03-15, 08:51 authored by Figshare Future Science GroupFigshare Future Science Group, Amirhossein Azhie, Robert C. Grant, Michael Herman, Lisa Wang, Jennifer J. Knox, Mamatha Bhat|
Allowed Therapies Prohibited or Restricted Therapies Biological specimens (Plans for collection, laboratory evaluation, and storage of specimens) Confidentiality Retention of Patient Records and Study Files |
